Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
7 evidence topics · 4 sources
Phase 1 bridging study: aroxybutynin 2.3 mg versus racemic oxybutynin 5 mg (APC-001)
Phase 1: components given alone and in combination, and time to maximum concentration (APC-001 and APC-002)
Metabolic pathways of the two components
Atomoxetine label: pharmacokinetic parameters by CYP2D6 metabolizer type
| Parameter | Other CYP2D6 metabolizer types | CYP2D6 poor metabolizers |
|---|---|---|
| Accumulation | “1.1-fold” | “3.3-fold” |
| Absolute bioavailability | “63%” | “94%” |
| Median time to maximum concentration | “1 hour” | “2.5 hour” |
| Atomoxetine half-life | “5.2 hours” | “21.6 hours” |
| Atomoxetine apparent oral clearance | “0.35 L/hr/kg” | “0.03 L/hr/kg” |
| Primary metabolic pathways | “CYP2D6” | “Other CYP enzymes” |
Atomoxetine label: food effect, distribution, excretion, and exposure in CYP2D6 poor metabolizers
Oxybutynin label: R-oxybutynin and S-oxybutynin after a single 10 mg extended-release dose
| Parameter | R-oxybutynin | S-oxybutynin |
|---|---|---|
| Cmax (ng/mL), mean (SD) | “1.0 (0.6)” | “1.8 (1.0)” |
| Tmax (h), mean (SD) | “12.7 (5.4)” | “11.8 (5.3)” |
| Half-life (h), mean (SD) | “13.2 (6.2)” | “12.4 (6.1)” |
| AUCinf (ng•h/mL), mean (SD) | “21.3 (12.2)” | “39.5 (21.2)” |